RT Journal Article
T1 Monoamino oxidase alleles correlate with the presence of essential hypertension among hypogonadic patients.
A1 Royo, José Luis
A1 Castellano-Castillo, Daniel
A1 Ruiz-Galdon, Maximiliano
A1 Molina-Vega, María
A1 Cardona, Fernando
A1 Tinahones, Francisco J
A1 Fernández-García, José C
A1 Reyes-Engel, Armando
K1 MAOA
K1 MAOB
K1 hypertension
K1 hypogonadism
AB Monoamine oxidase (MAO) activity has been traditionally implicated in blood pressure through its effects on biogenic amine levels such as catecholamines, serotonin, and dopamine. Nowadays, this role is considered relegated to side-effects such as orthostatic hypotension and/or hypertensive crisis derived from MAO-inhibitory treatments in patients with psychiatric disease. In the present work we have found an association between a polymorphic variant of MAOB gene and arterial hypertension in obese hypogonadic patients. The study cases comprised a series of 219 nondiabetic males with a body mass index ≥30 kg/m2 and aged  MAOB rs3027452-A allele carriers were significantly over-represented among hypertensive (HT) patients (25.49%) in comparison to either the non-HT patients (10%, OR = 3.079 CI95 [1.364-6.952], p = .005, Chi-square test) and the control population series of nonobese nor hypogonadic males (also 10%, p = .003 Chi-square test). Upon adjusted, an independent association was shown with the hypogonadic group with hypertension when compared with nonhypertensive hypogonadics (Beta = 3.653, p = .005). When quantitative analysis was performed, hypertensive patients harboring rs3027452-A allele showed higher systolic blood pressure values (p = .038, Mann-Whitney U-test) as well as an increased Systolic-Diastolic range despite following HT treatment (∆mmHg 54 vs. 48 for rs3027452-A and rs3027452-G respectively, p-value .019, Mann-Whitney U-test). Previous studies on MAOB revealed that rs3027452-A allele has been correlated to a lower activity of the enzyme, what gives a functional evidence over our observation. If this result could be extrapolated to other hypertensive patient groups, it would implicate a review of the markers and therapeutic targets on human hypertension.
YR 2019
FD 2019-11-19
LK http://hdl.handle.net/10668/14712
UL http://hdl.handle.net/10668/14712
LA en
DS RISalud
RD Apr 4, 2025